BALTIMORE, Sept. 11, 2024 ~ In a recent press release, Previse, a company specializing in gastrointestinal health, announced the publication of a study in Diagnostics showcasing the analytical validation of their groundbreaking DNA methylation test, Esopredict. This test is designed to identify patients with precancerous Barrett's esophagus (BE) who are at risk of developing high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) in the future.

According to Sarah Laun, PhD and Vice President of Research and Development at Previse, this new study serves as a complement to Esopredict's previously published clinical validation study. Laun stated that the results of this analytical validation demonstrate the strong performance of the Esopredict assay, which is conducted in Previse's CLIA laboratory located in Baltimore.

More on Marylandian

• Researchers uncover method to detect cancer with hair
• InventHelp Inventor Develops Pre- Signed Signature Pad for the Visually Impaired (DCD-514)
• Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
• 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
• Leading Venture Capital Firms Recognize Wzzph Exchange's Technical Architecture and Security Framework as Industry Benchmark

The publication, titled "Analytical Validation of Esopredict: An Epigenetic Prognostic Assay for Patients with Barrett's Esophagus," provides rigorous confirmation of the robustness and reproducibility of Esopredict. The data also showcases the high precision and reproducibility of the assay across various levels of risk. This further solidifies Esopredict as a reliable tool for identifying patients at risk for developing BE-related cancers.

---

Show All News | Report Violation